STOCK TITAN

Kura Oncology to Participate in Three Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Kura Oncology, Inc. announced that its CEO, Troy Wilson, will participate in three upcoming investor conferences. The conferences include the TD Cowen Fall Oncology Innovation Summit, the Stifel 2023 Healthcare Conference, and the Jefferies London Healthcare Conference. Live audio webcasts will be available on Kura's website.
Positive
  • None.
Negative
  • None.

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences.

  • A virtual fireside chat at the TD Cowen Fall Oncology Innovation Summit: Insights for SITC and ASH event at 12:00 p.m. ET / 9:00 a.m. PT on November 3, 2023;
  • A fireside chat at the Stifel 2023 Healthcare Conference in New York at 11:30 a.m. ET / 8:30 a.m. PT on November 14, 2023; and
  • A fireside chat at the Jefferies London Healthcare Conference in London at 9:30 a.m. GMT / 5:30 a.m. ET / 2:30 a.m. PT on November 16, 2023.

Live audio webcasts will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following all three events.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia (AML) patients with high unmet need. Kura is currently enrolling patients in a Phase 2 registration-directed trial of ziftomenib in NPM1-mutant relapsed or refractory AML (KOMET-001). The Company is also conducting a series of studies to evaluate ziftomenib in combination with current standards of care, beginning with venetoclax/azacitidine and standard induction cytarabine/daunorubicin chemotherapy in NPM1-mutant and KMT2A-rearranged newly diagnosed and relapsed/refractory AML (KOMET-007). Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with other targeted therapies (FIT-001). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on Twitter and LinkedIn.

Contacts

Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com

Media:
Alexandra Weingarten
Senior Manager, Corporate Communications
(858) 500-8822
alexandra@kuraoncology.com


FAQ

What did Kura Oncology announce?

Kura Oncology announced that its CEO, Troy Wilson, will participate in three upcoming investor conferences.

When and where are the conferences?

The conferences include the TD Cowen Fall Oncology Innovation Summit on November 3, the Stifel 2023 Healthcare Conference on November 14, and the Jefferies London Healthcare Conference on November 16.

Where can I access the webcasts?

The live audio webcasts will be available on Kura Oncology's website at www.kuraoncology.com.

Will there be replays of the events?

Yes, archived replays will be available on Kura Oncology's website following all three events.

Kura Oncology, Inc.

NASDAQ:KURA

KURA Rankings

KURA Latest News

KURA Stock Data

1.60B
48.24M
1.75%
105.55%
13.67%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About KURA

at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.